Tolvaptan in autosomal dominant polycystic kidney disease

Free article

Comment

Vicente E Torres et al. N Engl J Med. 2013.

Free article

. 2013 Mar 28;368(13):1259.

doi: 10.1056/NEJMc1300762.

No abstract available

Comment on

Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
Tolvaptan in autosomal dominant polycystic kidney disease.
Spital A. Spital A. N Engl J Med. 2013 Mar 28;368(13):1257. doi: 10.1056/NEJMc1300762. N Engl J Med. 2013. PMID: 23534569 No abstract available.
Tolvaptan in autosomal dominant polycystic kidney disease.
Kher A. Kher A. N Engl J Med. 2013 Mar 28;368(13):1257-8. doi: 10.1056/NEJMc1300762. N Engl J Med. 2013. PMID: 23534570 No abstract available.
Tolvaptan in autosomal dominant polycystic kidney disease.
Sexton DJ. Sexton DJ. N Engl J Med. 2013 Mar 28;368(13):1258. doi: 10.1056/NEJMc1300762. N Engl J Med. 2013. PMID: 23534571 No abstract available.
Tolvaptan in autosomal dominant polycystic kidney disease.
Jouret F, Krzesinski JM. Jouret F, et al. N Engl J Med. 2013 Mar 28;368(13):1258-9. doi: 10.1056/NEJMc1300762. N Engl J Med. 2013. PMID: 23534572 No abstract available.